Vitiligo, methotrexate studies top weekly dermatology reads

Research finding that melanocyte-keratinocyte transplantation offered long-term repigmentation for vitiligo and other leukodermas was among the top read articles of the past week on Healio.com/Dermatology.

Other widely-read articles included findings in which researchers identified early signs and risk factors of methotrexate-induced epidermal necrosis:

Melanocyte-keratinocyte transplantation offers long-term repigmentation for vitiligo, leukodermas

Patients with vitiligo and other leukodermas experienced long-term repigmentation up to 72 months after treatment with a melanocyte-keratinocyte transplantation procedure, according to recently published study results in the Journal of the American Academy of Dermatology.

Iltefat H. Hamzavi

Iltefat H. Hamzavi, MD, of the dermatology department at Henry Ford Hospital, Detroit, and colleagues conducted a retrospective review of electronic records of 100 patients with vitiligo or other leukodermas who underwent melanocyte-keratinocyte transplantation procedure between January 2009 and April 2014. Read more

Factors of methotrexate-induced epidermal necrosis identified

Researchers identified early signs and risk factors of methotrexate-induced epidermal necrosis, and physicians should use caution when deciding when to prescribe methotrexate to high-risk patients, according to recently published study results in the Journal of the American Academy of Dermatology.

The researchers in Taiwan enrolled 24 patients with methotrexate-induced epidermal necrosis (MEN; mean age, 65.8 years; 13 men) and 150 methotrexate-tolerant controls (mean age, 40.7 years; 86 men) between 2007 and 2016. Read more

American Academy of Dermatology issues statement on sunscreen safety

The American Academy of Dermatology has released a statement on sunscreen, emphasizing that “sunscreen remains a safe, effective form of sun protection.”

The AAD statement was in response to the recently released guides by the Environmental Working Group and Consumer Reports that reviewed safety and efficacy of sunscreens, according to an AAD spokesperson. Read more

FDA accepts biologics license application for tildrakizumab for treating psoriasis

Sun Pharma announced that the FDA has accepted a biologics license application for tildrakizumab for treating moderate-to-severe plaque psoriasis.

Merck & Co. filed the biologics license application (BLA) for tildrakizumab, an investigational humanized, anti-IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23. Sun Pharmaceutical Industries Ltd.'s subsidiary acquired worldwide rights to tildrakizumab from Merck in 2014, according to a news release. Read more

Hidradenitis suppurativa uncommon in US, mainly affects females, young adults

Hidradenitis suppurativa is an uncommon disease in the United States that more often affects females, young adults, black and biracial patients, according to study results recently published in JAMA Dermatology.

Amit Garg, MD, of the dermatology department at Hofstra Norwell School of Medicine in North Hyde Park, New York, and colleagues used a multi-institutional data analytics and research platform to determine a heterogenous population-based sample of more than 48 million patients across all U.S. Census regions. Read more